Monopar Therapeutics Inc
MNPR80.950USD
+0.190+0.24%
終値 11/07, 16:00（ET）15分遅れの株価
496.02M時価総額
損失額直近12ヶ月PER
詳細情報 Monopar Therapeutics Inc 企業名
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
Monopar Therapeutics Incの企業情報
企業コードMNPR
会社名Monopar Therapeutics Inc
上場日Dec 19, 2019
最高経営責任者「CEO」Dr. Chandler D. Robinson, M.D.
従業員数16
証券種類Ordinary Share
決算期末Dec 19
本社所在地1000 Skokie Blvd Ste 350
都市WILMETTE
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号60091-1146
電話番号18473880349
ウェブサイトhttps://www.monopartx.com/
企業コードMNPR
上場日Dec 19, 2019
最高経営責任者「CEO」Dr. Chandler D. Robinson, M.D.
Monopar Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
79.42K
+8.10%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
79.42K
+8.10%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Tue, Aug 19
更新時刻: Tue, Aug 19
株主統計
種類
株主統計
株主統計
比率
Janus Henderson Investors
17.73%
Gem Pharmaceuticals LLC
9.24%
Adage Capital Management, L.P.
9.06%
RA Capital Management, LP
7.73%
AstraZeneca PLC
5.86%
他の
50.37%
株主統計
株主統計
比率
Janus Henderson Investors
17.73%
Gem Pharmaceuticals LLC
9.24%
Adage Capital Management, L.P.
9.06%
RA Capital Management, LP
7.73%
AstraZeneca PLC
5.86%
他の
50.37%
種類
株主統計
比率
Investment Advisor/Hedge Fund
20.88%
Corporation
19.21%
Hedge Fund
14.05%
Venture Capital
7.73%
Investment Advisor
5.43%
Individual Investor
4.80%
Research Firm
0.19%
Pension Fund
0.12%
Bank and Trust
0.06%
他の
27.52%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
99
3.34M
50.46%
+135.23K
2025Q2
76
5.07M
82.91%
-355.61K
2025Q1
72
5.03M
83.96%
+455.96K
2024Q4
54
4.84M
79.28%
+1.76M
2024Q3
40
1.90M
50.69%
+25.14K
2024Q2
43
1.96M
52.51%
+123.52K
2024Q1
46
1.91M
52.92%
+136.66K
2023Q4
44
1.88M
67.20%
+125.61K
2023Q3
42
1.87M
67.45%
+153.91K
2023Q2
38
1.84M
66.75%
+138.58K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Janus Henderson Investors
1.17M
17.73%
+37.96K
+3.35%
Jun 30, 2025
Gem Pharmaceuticals LLC
611.08K
9.24%
--
--
Apr 04, 2025
Adage Capital Management, L.P.
599.20K
9.06%
--
--
Jun 30, 2025
RA Capital Management, LP
511.21K
7.73%
--
--
Jun 30, 2025
AstraZeneca PLC
387.33K
5.86%
+387.33K
--
Oct 23, 2024
Tactic Pharma LLC
272.03K
4.11%
-550.23K
-66.92%
Sep 24, 2025
The Vanguard Group, Inc.
86.49K
1.31%
+31.25K
+56.59%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
183.97K
2.78%
+175.22K
+2003.49%
Jun 30, 2025
Point72 Asset Management, L.P.
104.02K
1.57%
-64.14K
-38.14%
Jun 30, 2025
Adar1 Capital Management LLC
100.97K
1.53%
+200.00
+0.20%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
比率0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0.05%
iShares Russell 2000 Growth ETF
比率0.02%
Proshares Ultra Russell 2000
比率0.01%
Global X Russell 2000 ETF
比率0.01%
ProShares Hedge Replication ETF
比率0.01%
ProShares UltraPro Russell2000
比率0.01%
iShares Russell 2000 ETF
比率0.01%
Avantis US Small Cap Equity ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
日付
種類
比率
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
